Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The activity of the endogenous kinase carrying the E17K mutation immunoprecipitated by tumour tissue was significantly higher compared with the wild-type kinase immunoprecipitated by the adjacent normal tissue as determined both by in vitro kinase assay using a consensus peptide as substrate and by in vivo analysis of the phosphorylation status of AKT1 itself (pT308, pS473) or of known downstream substrates such as GSK3 (pS9/S22) and p27 (T198).
|
18256540 |
2008 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two mutations were identified in the tumor tissue by NGS and sanger sequencing: AKT1 E17K and BRAF (B-Raf proto-oncogene, serine/threonine kinase) V600E.
|
31546071 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although AKT1-mutant tumor specimens were often found to harbor concurrent alterations in other driver genes, a subset of specimens harboring AKT1 (E17K) as the only known driver alteration was also identified.
|
27515171 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Results In patients with AKT1 E17K-mutant tumors (n = 52) and a median of five lines of prior therapy, the median PFS was 5.5 months (95% CI, 2.9 to 6.9 months), 6.6 months (95% CI, 1.5 to 8.3 months), and 4.2 months (95% CI, 2.1 to 12.8 months) in patients with estrogen receptor-positive breast, gynecologic, and other solid tumors, respectively.
|
28489509 |
2017 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compound 21a also served as a potent inhibitor of the AKT1-E17K mutant protein and inhibited tumor growth in a human xenograft mouse model of endometrial adenocarcinoma.
|
27305487 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The data show that tumors with AKT1(E17K) mutations are rational therapeutic targets for AKT inhibitors, although combinations with other targeted agents may be required where activating oncogenic mutations of other proteins are present in the same tumor.
|
26351323 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To enable prospective screening for the low prevalence AKT1 E17K mutation, we have developed and validated a competitive allele-specific TaqMan® PCR (castPCR™) assay for mutation detection in formalin-fixed paraffin-embedded (FFPE) tumor tissue.
|
28472036 |
2017 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The AKT1 (E17K) mutation in the tumor was not detectable in all investigated specimens.
|
26077595 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Knockin of the AKT1 E17K hotspot mutation on this PIK3CA wild-type background restored pathway signaling, proliferation, and tumor growth in vivo.
|
23888070 |
2013 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report that in immortalized human bronchial epithelial cells (BEAS-2B cells) mutant AKT1-E17K promotes anchorage-dependent and -independent proliferation, increases the ability to migrate, invade as well as to survive and duplicate in stressful conditions, leading to the emergency of cells endowed with the capability to form aggressive tumours at high efficiency.
|
26053093 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The AKT1 (E17K) mutation has been reported in some tumour types (breast, colorectal, ovarian and lung cancers), and it is of interest which tumour types other than those possess the E17K mutation.
|
19491896 |
2009 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The whole exome sequencing showed that AKT1 E17K mutation was high (26.316%) in tumor tissue, and dynamic monitoring of circulating tumor DNA indicated that AKT1 E17K mutation rate was increasing successively and highly consistent with tumor growth in peripheral blood.
|
31802899 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently, a somatic mutation in the AKT1 gene (E17K) was identified in a small proportion of human tumors.
|
19420344 |
2009 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results showed that activating mutations in either PIK3CA or AKT1 were identified in 20 tumors (67%); 19 tumors had PIK3CA mutations (63%; 13 in exon 20 and 6 in exon 9), and 1 had an AKT1 E17K mutation (3%).
|
27184479 |
2016 |